Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis

Journal of the American Academy of Dermatology

Volumn 70, Issue 6, 2014, Pages 1067-1075

  Sigurdardottir, Gunnthorunn ^a   Ekman, Anna Karin ^a   Ståhle, Mona ^b   Bivik, Cecilia ^a   Enerbäck, Charlotta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

cardiovascular risk; matrix metalloproteinase 9; myeloperoxidase; psoriasis; soluble E selectin; soluble intercellular adhesion molecule 1; soluble vascular cell adhesion molecule 1; total plasminogen activator inhibitor 1; tumor necrosis factor alfa inhibitor; ultraviolet B

Indexed keywords

ETANERCEPT; PLASMINOGEN ACTIVATOR INHIBITOR 1; AUTACOID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; PEROXIDASE; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; METABOLIC SYNDROME X; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; ULTRAVIOLET B RADIATION; WAIST HIP RATIO; ADULT; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; E-SELECTIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PEROXIDASE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 84901231932     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.12.044     Document Type: Article

References (46)

1. A. Menter, C.E. Griffiths, P.W. Tebbey, E.J. Horn, W. Sterry International Psoriasis Council Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community J Eur Acad Dermatol Venereol 24 2010 1371 1377
2. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
3. L. Mallbris, O. Akre, F. Granath, L. Yin, B. Lindelof, and A. Ekbom et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients Eur J Epidemiol 19 2004 225 230
4. J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, and X. Wang et al. The risk of stroke in patients with psoriasis J Invest Dermatol 129 2009 2411 2418
5. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
6. J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, and X. Wang et al. The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 2007 1493 1499
7. N.N. Mehta, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database Eur Heart J 31 2010 1000 1006
8. S. Prodanovich, R.S. Kirsner, J.D. Kravetz, F. Ma, L. Martinez, and D.G. Federman Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality Arch Dermatol 145 2009 700 703
9. Y. Wang, J. Chen, Y. Zhao, L. Geng, F. Song, and H.D. Chen Psoriasis is associated with increased levels of serum leptin Br J Dermatol 158 2008 1134 1135
10. S. Boehncke, R. Salgo, J. Garbaraviciene, H. Beschmann, K. Hardt, and S. Diehl et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study J Eur Acad Dermatol Venereol 25 2011 1187 1193
11. A.K. Ekman, G. Sigurdardottir, M. Carlstrom, N. Kartul, M.C. Jenmalm, and C. Enerback Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment Acta Derm Venereol 93 2013 527 531
12. World Health Organization (WHO). Waist circumference and waist-hip ratio: Report of a WHO expert consultation, Geneva, December 8-11, 2008. Geneva, Switzerland: WHO. 2011.
13. S. Boehncke, D. Thaci, H. Beschmann, R.J. Ludwig, H. Ackermann, and K. Badenhoop et al. Psoriasis patients show signs of insulin resistance Br J Dermatol 157 2007 1249 1251
14. W.H. Boehncke, S. Boehncke, A.M. Tobin, and B. Kirby The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity Exp Dermatol 20 2011 303 307
15. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE); a randomized trial and cohort study JAMA 286 2001 64 70
16. R. Ghazizadeh, H. Shimizu, M. Tosa, and M. Ghazizadeh Pathogenic mechanisms shared between psoriasis and cardiovascular disease Int J Med Sci 7 2010 284 289
17. F. Späh Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach Br J Dermatol 159 Suppl 2008 10 17
18. I. Malik, J. Danesh, P. Whincup, V. Bhatia, O. Papacosta, and M. Walker et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis Lancet 358 2001 971 976
19. S.A. Hope, and I.T. Meredith Cellular adhesion molecules and cardiovascular disease, part II: their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction Intern Med J 33 2003 450 462
20. S. Blankenberg, H.J. Rupprecht, C. Bickel, D. Peetz, G. Hafner, and L. Tiret et al. Circulating cell adhesion molecules and death in patients with coronary artery disease Circulation 104 2001 1336 1342
21. B. Torres-Alvarez, J.P. Castanedo-Cazares, C. Fuentes-Ahumada, and B. Moncada The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis J Eur Acad Dermatol Venereol 21 2007 334 339
22. O.J. de Boer, I.M. Wakelkamp, S.T. Pals, N. Claessen, J.D. Bos, and P.K. Das Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin Arch Dermatol Res 286 1994 304 311
23. E.A. Dowlatshahi, E.A. van der Voort, L.R. Arends, and T. Nijsten Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis Br J Dermatol 169 2013 266 282
24. M.H. Tayebjee, G.Y. Lip, and R.J. MacFadyen Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance Curr Med Chem 12 2005 917 925
25. N. Eldrup, M.L. Gronholdt, H. Sillesen, and B.G. Nordestgaard Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis Circulation 114 2006 1847 1854
26. S. Suomela, A.L. Kariniemi, E. Snellman, and U. Saarialho-Kere Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions Exp Dermatol 10 2001 175 183
27. P. Cordiali-Fei, E. Trento, G. D'Agosto, V. Bordignon, A. Mussi, and M. Ardigo et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions Ann N Y Acad Sci 1110 2007 578 589
28. E. Buommino, A. De Filippis, F. Gaudiello, A. Balato, N. Balato, and M.A. Tufano et al. Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNF-alpha therapy Arch Dermatol Res 304 2012 481 485
29. S. Baldus, C. Heeschen, T. Meinertz, A.M. Zeiher, J.P. Eiserich, and T. Munzel et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445
30. P.J. Declerck, and A. Gils Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin Semin Thromb Hemost 39 2013 356 364
31. M.C. Alessi, F. Peiretti, P. Morange, M. Henry, G. Nalbone, and I. Juhan-Vague Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease Diabetes 46 1997 860 867
32. H.M. Gissler, R. Frank, and M.D. Kramer Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis Br J Dermatol 128 1993 612 618
33. H.J. Nielsen, I.J. Christensen, M.N. Svendsen, U. Hansen, K. Werther, and N. Brunner et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis Inflamm Res 51 2002 563 567
34. S. Gerdes, M. Rostami-Yazdi, and U. Mrowietz Adipokines and psoriasis Exp Dermatol 20 2011 81 87
35. E. Racz, E.P. Prens, D. Kurek, M. Kant, D. de Ridder, and S. Mourits et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways J Invest Dermatol 131 2011 1547 1558
36. S.C. Weatherhead, P.M. Farr, D. Jamieson, J.S. Hallinan, J.J. Lloyd, and A. Wipat et al. Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation J Invest Dermatol 131 2011 1916 1926
37. J.J. Wu, K.Y.T. Poon, J.C. Channual, and A.Y.J. Shen Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis Arch Dermatol 148 2012 1244 1250
38. L.T. Jacobsson, C. Turesson, J.A. Nilsson, I.F. Petersson, E. Lindqvist, and T. Saxne et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis Ann Rheum Dis 66 2007 670 675
39. S. Prodanovich, F. Ma, J.R. Taylor, C. Pezon, T. Fasihi, and R.S. Kirsner Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis J Am Acad Dermatol 52 2005 262 267
40. K. Dahlman-Ghozlan, J.D. Heilborn, and E. Stephansson Circulating levels of soluble E-selectin, ICAM-1 and VCAM-1 in bullous pemphigoid during low-dose methotrexate therapy: a prospective study Exp Dermatol 9 2000 336 340
41. J. Romani, A. Caixas, J.M. Carrascosa, M. Ribera, M. Rigla, and J. Luelmo Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis Br J Dermatol 166 2012 1237 1244
42. S. Coimbra, H. Oliveira, F. Reis, L. Belo, S. Rocha, and A. Quintanilha et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study Am J Clin Dermatol 11 2010 423 432
43. S. Coimbra, H. Oliveira, F. Reis, L. Belo, S. Rocha, and A. Quintanilha et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumor necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy Br J Dermatol 163 2010 1282 1290
44. K.S. Anderson, S. Petersson, J. Wong, E. Shubbar, N.N. Lokko, and M. Carlstrom et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris Br J Dermatol 163 2010 1085 1089
45. C. Enerback Soluble biomarkers in psoriasis Eur J Dermatol 21 2011 844 850
46. S. Coimbra, H. Oliveira, L. Belo, A. Figueiredo, P. Rocha-Pereira, and A. Santos-Silva Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study Am J Clin Dermatol 14 2013 49 53